ACR

New Year May Bring New Lupus Treatments

November 13, 2020

At this year's annual meeting of the American College of Rheumatology, there were a number of studies presented on different treatments for lupus. It's an exciting time in lupus research says Dr. Richard Furie, chief of rheumatology at Northwell Health in New York. In today's one on one interview, he breaks down some of the lupus studies presented at the meeting

ACR Set to Issue Updated Treatment Guidelines

November 12, 2020

The American College of Rheumatology is expected to issue updated treatment guidelines for rheumatoid arthritis no later than spring 2021. The new guidelines will include recommended uses for biologics approved since the last update in 2015―including JAK inhibitors.

ACR Conference Roundup: New RA Treatment Guidelines Preview

November 12, 2020

In this week's news roundup from Rheumatology Network, we highlight studies presented at the annual meeting of the American College of Rheumatology, which wrapped this week. Among the stories we covered included a preview of the soon-to-be released rheumatoid arthritis guidelines, promising new treatments for lupus nephritis and advances in osteoporosis care. Learn more in today's news roundup.

Medication Management Preferences Depend on Case Burden

November 12, 2020

A survey of rheumatologists in the United States found that their prescriptions of medications such as NSAIDs, biologics and steroids during the COVID-19 pandemic is based on regional case burden rather than American College of Rheumatology guidance.

Q&A: Methotrexate and Tuberculosis

November 12, 2020

Tuberculosis screening and ongoing clinical care is needed for patients prescribed methotrexate, particularly if co-administered with corticosteroids or other immunosuppressants, who live in areas where tuberculosis is common, according to researchers recently reporting at the annual meeting of the American College of Rheumatology.

Tofacitinib, Adalimumab, Methotrexate Show Similar Influenza Adverse Events in RA

November 10, 2020

In a study that examined the influenza adverse events (AEs) of tofacitinib (Xeljanz, Pfizer) in patients with rheumatoid arthritis, similar AEs were seen with tofacitinib, adalimumab, methotrexate, and placebo, and between different tofacitinib doses and patient age groups, according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

Q&A: Hydroxychloroquine and Heart Rhythm in SLE

November 10, 2020

Patients with systemic lupus erythematous (SLE) who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals on electrocardiogram (EKG), even if they have chronic kidney disease (CKD), according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

Rheumatic Disease Patients Bear the Brunt of Antimalarial Shortages

November 10, 2020

Lessons learned from antimalarial drug shortages during the COVID-19 pandemic: rheumatic disease patients in African and South-East Asia had difficulty obtaining antimalarials as compared to counterparts in the Americas and Europe. Shortages led to worse mental and physical health outcomes. Antimalarials did not protect patients from COVID-19.

Corticosteroids Not a Contributor in Advanced Knee Osteoarthritis

November 09, 2020

The use of corticosteroid injections may not be associated with the progression of knee osteoarthritis to the point of total knee replacement any more than the use of hyaluronic acid, according to a presentation made today at the American College of Rheumatology annual meeting.

COVID-19 Severity Elevated for Black and Latinx Rheumatic Patients

November 09, 2020

Black and Latinx COVID-19 patients in the United States who suffer from rheumatic conditions are more likely to require hospitalization and invasive ventilation than their White counterparts, a new study suggests.

Artificial Intelligence RA Study Shows a Five-Fold Increase in ACR70 Response

November 08, 2020

In a study presented at the annual meeting of the American College of Rheumatology, UK researchers showcase a study in which artificial intelligence was successfully used to identify ACPA positivity and CRP of greater than 12.3 mg/L to identify rheumatoid arthritis patients more likely to respond to sarilumab.

Podcast: ACR Annual Meeting Preview

November 07, 2020

Welcome to Overdrive, the podcast from Rheumatology Network. This week marks the start of the 2020 annual meeting of the American College of Rheumatology. Some of the studies we're covering include new therapies for lupus nephritis, the impact of COVID-19 on rheumatic disease patients, and pregnancy outcomes in ILD patients. Today, Dr. Fotios Koumpouras of the Yale School of Medicine, highlights some studies you won't want to miss at this year's meeting.

Abatacept for JIA Passes Long-term Safety Trial

November 07, 2020

In a study that examined the long-term effectiveness of intravenous and subcutaneous abatacept (Orencia, Bristol-Myers Squibb) in patients with juvenile idiopathic arthritis (JIA), the treatment was safe and well-tolerated with no new safety risks identified, according to researchers reporting at the annual meeting of the American College of Rheumatology on Saturday.

ACR Annual Meeting Highlights: Lupus Nephritis, COVID-19, Safe Pregnancies

November 06, 2020

This week marks the start of the 2020 annual meeting of the American College of Rheumatology. Some of the studies we're covering include new therapies for lupus nephritis. Belimumab was shown recently to improve renal outcomes in lupus nephritis patients when added to standard of care. It will likely emerge as a significant treatment option, says Dr. Fotios Koumpouras, fellowship program director for rheumatology at Yale School of Medicine and a Rheumatology Network board member. Dr. Koumpouras breaks down his highlights in this interview.

Secukinumab Improves Signs and Symptoms of Axial Spondyloarthritis

November 05, 2020

An analysis of patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with an elevated C-reactive protein (CRP) and/or evidence of sacroiliitis on magnetic resonance imaging (MRI) found that secukinumab (Cosentyx, Novartis) use resulted in numerically higher treatment response rates than placebo.